CD40 and neoplasm: This is supported by studies from our laboratory showing that CD8+ T cells are important anti-tumor effector cells during IL-2/CD40 treatment (26, 29), and other studies showing that DCs, CD8+ T cells and IFN-γ are required for IL-2/CD40-mediated tumor regression (89–92).